
Raymond James raises Rapport Therapeutics price target to $86 after positive Phase 2 trial for bipolar mania drug.
Raymond James increased its price target for Rapport Therapeutics to $86 following positive Phase 2 trial results of RAP-219, a drug treating acute bipolar mania. The trial showed statistically significant improvement in patients and a favorable safe...





